J&J's Tremfya and Carvykti Hit Key Endpoints in Psoriatic Arthritis and Myeloma Trials
JNJ sits 54% above its 52-week low of $175.91 on light trading volume (0.2× avg).
Summary
J&J reported positive data from two clinical programs. Tremfya met primary and secondary endpoints in the Phase 4 STAR trial for psoriatic arthritis with axial involvement, showing significant improvement in composite disease activity scores and reduced sacroiliac joint inflammation. Carvykti's five-year follow-up from CARTITUDE-2 Cohort A showed 50% of relapsed/refractory multiple myeloma patients remained progression-free after a single infusion, with median PFS of 60.5 months and 69.2% overall survival. These results strengthen the commercial positioning of both drugs, particularly Carvykti's long-term durability claim in a competitive CAR-T market. The stock is trading near its 52-week high, and this news adds to a string of positive pipeline updates this year, including the OTTAVA robotic system clearance and Tecvayli/Talvey combination data. No new safety signals were reported for either therapy.
At the time of this announcement, JNJ was trading at $270.20 on NYSE in the Life Sciences sector, with a market capitalization of approximately $651.2B. The 52-week trading range was $175.91 to $281.07. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Benzinga.